Published online before print March 19, 2007, doi: 10.1161/CIRCULATIONAHA.106.653964
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1754-1761.)
© 2007 American Heart Association, Inc.
Heart Failure |
Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure
From the Department of Internal Medicine I, Center for Cardiovascular Medicine, University of Würzburg, Würzburg, Germany.
Correspondence to Dr Stefan Störk, MD, PhD, University of Würzburg, Department of Internal Medicine I, Center for Cardiovascular Medicine, Klinikstrasse 6–8, D-97070 Würzburg, Germany. E-mail stoerk_s{at}klinik.uni-wuerzburg.de
Received July 24, 2006; accepted January 19, 2007.
Background— In patients with systolic heart failure, high levels of circulating aldosterone are associated with an adverse prognosis, and mineralocorticoid receptor blockade improves survival. The prognostic significance of cortisol that may also bind and activate the mineralocorticoid receptor in chronic heart failure is unknown.
Methods and Results— Serum levels of cortisol and aldosterone were quantified in a prospective cohort study of 294 consecutive patients with chronic heart failure [48% were in New York Heart Association functional class III or IV; 58% had systolic heart failure]. During a median follow-up of 803 days (interquartile range, 314 to 1098), 79 patients died (27.3% mortality rate). Cortisol and aldosterone were independent predictors of increased mortality risk in Cox regression analyses adjusted for age, sex, New York Heart Association functional class, C-reactive protein, N-terminal pro-brain natriuretic peptide, sodium, and hypercholesterolemia. The hazard ratio for highest versus lowest tertile of cortisol was 2.72 [95% confidence interval [CI], 1.38 to 5.36; P=0.004], and the hazard ratio for aldosterone was 2.19 (95% CI, 1.23 to 3.93; P=0.008). Patients with both cortisol and aldosterone levels above the respective medians had a 3.4-fold higher mortality risk compared with subjects with both corticosteroids below the median (95% CI, 1.54 to 7.46; P=0.0001). Addition of cortisol and aldosterone levels to the fully adjusted model significantly improved the discriminatory power [increase in Harrell’s C-statistic from 0.80 (95% CI, 0.70 to 0.90) to 0.86 (95% CI, 0.79 to 0.94; P<0.001 for change].
Conclusions— In patients with chronic heart failure, higher serum levels of both cortisol and aldosterone were independent predictors of increased mortality risk that conferred complementary and incremental prognostic value.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  E M Freel, I K Tsorlalis, J D Lewsey, R Latini, A P Maggioni, S Solomon, B Pitt, J M C Connell, and J J V McMurray Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study Heart, December 1, 2009; 95(23): 1920 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamaji, T. Tsutamoto, C. Kawahara, K. Nishiyama, T. Yamamoto, M. Fujii, and M. Horie Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure: The Impact of Oxidative Stress Circ Heart Fail, November 1, 2009; 2(6): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Bosch, H. Riese, A. Dietrich, J. Ormel, F. C. Verhulst, and A. J. Oldehinkel Preadolescents' Somatic and Cognitive-Affective Depressive Symptoms Are Differentially Related to Cardiac Autonomic Function and Cortisol: The TRAILS Study Psychosom Med, November 1, 2009; 71(9): 944 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maturana, S. Lenglet, M. Python, S. Kuroda, and M. F. Rossier Role of the T-Type Calcium Channel CaV3.2 in the Chronotropic Action of Corticosteroids in Isolated Rat Ventricular Myocytes Endocrinology, August 1, 2009; 150(8): 3726 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Somekawa, K. Imagawa, N. Naya, Y. Takemoto, K. Onoue, S. Okayama, Y. Takeda, H. Kawata, M. Horii, T. Nakajima, et al. Regulation of Aldosterone and Cortisol Production by the Transcriptional Repressor Neuron Restrictive Silencer Factor Endocrinology, July 1, 2009; 150(7): 3110 - 3117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yoshikawa, M. Nagasaki, M. Sano, S. Tokudome, K. Ueno, N. Shimizu, S. Imoto, S. Miyano, M. Suematsu, K. Fukuda, et al. Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1363 - E1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Funder The Off-Target Effects of Torcetrapib Endocrinology, May 1, 2009; 150(5): 2024 - 2026. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rengo, A. Lymperopoulos, C. Zincarelli, M. Donniacuo, S. Soltys, J. E. Rabinowitz, and W. J. Koch Myocardial Adeno-Associated Virus Serotype 6-{beta}ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure Circulation, January 6, 2009; 119(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pitt The measurement of plasma aldosterone in patients post-myocardial infarction Eur. Heart J., October 2, 2008; 29(20): 2451 - 2452. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Molloy, L. Perkins-Porras, P. C. Strike, and A. Steptoe Type-D Personality and Cortisol in Survivors of Acute Coronary Syndrome Psychosom Med, October 1, 2008; 70(8): 863 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Rossier, S. Lenglet, L. Vetterli, M. Python, and A. Maturana Corticosteroids and Redox Potential Modulate Spontaneous Contractions in Isolated Rat Ventricular Cardiomyocytes Hypertension, October 1, 2008; 52(4): 721 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bauer, G.A. MacGowan, A. Blain, K. Bushby, and V. Straub Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy Cardiovasc Res, September 1, 2008; 79(4): 652 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Molnar, C. Lindschau, G. Dubrovska, P. R. Mertens, T. Kirsch, M. Quinkler, M. Gollasch, S. Wresche, F. C. Luft, D. N. Muller, et al. Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells Hypertension, May 1, 2008; 51(5): 1372 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Krug and M. Ehrhart-Bornstein Aldosterone and Metabolic Syndrome: Is Increased Aldosterone in Metabolic Syndrome Patients an Additional Risk Factor? Hypertension, May 1, 2008; 51(5): 1252 - 1258. [Full Text] [PDF]
|
|
|
|
|
|
B. P. Shapiro, T. E. Owan, S. Mohammed, M. Kruger, W. A. Linke, J. C. Burnett Jr, and M. M. Redfield Mineralocorticoid Signaling in Transition to Heart Failure With Normal Ejection Fraction Hypertension, February 1, 2008; 51(2): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R Walker Glucocorticoids and Cardiovascular Disease Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Krug, S. Kopprasch, C. G. Ziegler, S. Dippong, R. A. Catar, S. R. Bornstein, H. Morawietz, and M. Gekle Aldosterone Rapidly Induces Leukocyte Adhesion to Endothelial Cells: A New Link Between Aldosterone and Arteriosclerosis? Hypertension, November 1, 2007; 50(5): e156 - e157. [Full Text] [PDF]
|
|